Benzinga | Mar 16, 2021 08:29AM EDT

Evofem Biosciences Highlights Publication In American Journal Of Obstetrics And Gynecology Of AMPREVENCE Study Of EVO100 For Chlamydia And Gonorrhea Prevention

SAN DIEGO, March 16, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ:EVFM) today announced publication of the pivotal manuscript from the AMPREVENCE clinical trial in the highly respected American Journal of Obstetrics and Gynecology (AJOG). This double-blinded, placebo-controlled, multicenter study of EVO100 met its primary and secondary efficacy endpoints with statistically significant reductions in the risk of chlamydia and gonorrhea infections in women at high risk of infection.